Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Women's Health Rheumatology Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting Non-phase study NCT07313332

Exploring Resistance Exercise Training Plus High-Intensity Interval Training (ReHIIT) as Cancer Prehabilitation

Exploring Resistance Exercise Training Plus High-Intensity Interval Training (ReHIIT) as Cancer Prehabilitation — Recruiting • Non-phase study • Oncology • NCT07313332.

📅 14 Aug 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT07313332
Sponsor
University of Nottingham
Start
2026-01-01
ClinicaliQ Trial Snapshot
  • Exploring Resistance Exercise Training Plus High-Intensity Interval Training (ReHIIT) as Cancer Prehabilitation — Recruiting • Non-phase study • Oncology • NCT07313332.
  • What is being tested: A combined prehabilitation programme (ReHIIT) integrating resistance exercise training with high-intensity interval training in healthy adults to establish baseline physiological responses before application to colorectal cancer patients undergoing surgery.
  • Patient eligibility overview: This pilot study recruits healthy adults without cancer diagnosis to determine safety, feasibility, and physiological markers before advancing to colorectal cancer patients; this staged approach allows optimisation of the intervention protocol.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

Colorectal cancer is the fourth most common cancer in the UK. Prehabilitation, including exercise, can improve recovery from surgery. This pilot study investigates the combined effects of resistance and high-intensity interval training (ReHIIT) in healthy adults to establish baseline physiology and responses for comparison with cancer patients

Eligibility Snapshot
  • : * Participant is willing and able to give informed consent for participation in the study. * Availability and willingness to attend the Royal Derby Hospital site for a minimum of 8 exercise sessions and 2 assessment sessions across the study period.

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer
Oncology · 09 Sep 2026
Durvalumab combined with platinum-based chemotherapy is the recommended first-line treatment for untreated advanced or recurrent endometrial cancer, with olaparib addition considered based…
View guideline →
Clinical Brief
Pope pictured for first time since surgery and cancer diagnosis
Oncology · BBC Health · 16 Oct 2026
Pope Francis underwent lung cancer surgery at Gemelli Hospital in Rome; public appearance marks recovery milestone following diagnosis First photographic evidence post-operatively…
View brief →
Clinical Brief
‘My cancer spread while I waited months for surgery’: The cost of England’s cancer wait times
Oncology · BBC Health · 10 Sep 2026
England's cancer surgery waiting times have deteriorated despite government initiatives aimed at improving them, with patients experiencing significant delays that may allow…
View brief →
Clinical Brief
Heart trial after breast cancer has ‘improved my life’
Oncology · BBC Health · 02 Sep 2026
Women completing breast cancer treatment can safely discontinue cardioprotective medications (likely ACE inhibitors/beta-blockers) without adverse cardiac outcomes, based on evidence from a…
View brief →
Clinical Brief
Cancer patient told she will get drug which could make her life longer
Oncology · BBC Health · 17 Sep 2026
Sacituzumab govitecan is now available on the NHS for patients with incurable (metastatic triple-negative) breast cancer, following a revised cost-effectiveness assessment after…
View brief →
Clinical Brief
New hope for breast cancer patients as life-extending drug now on NHS in England
Oncology · BBC Health · 16 Sep 2026
Enhertu is now available on the NHS in England, extending median overall survival by approximately seven months in eligible breast cancer patients…
View brief →